No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ABBV241227P170000
- 0.28
- -1.32-82.50%
15min DelayClose Dec 20 16:00 ET
1.70High0.23Low
1.70Open1.60Pre Close190 Volume1.08K Open Interest170.00Strike Price6.33KTurnover25.49%IV3.34%PremiumDec 27, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.28Extrinsic Value100Contract SizeAmericanOptions Type-0.1161Delta0.0401Gamma627.07Leverage Ratio-0.1048Theta-0.0023Rho-72.82Eff Leverage0.0374Vega
Intraday
- 5D
- Daily
News
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
AbbVie Insiders Sell US$56m Of Stock, Possibly Signalling Caution
AbbVie Hits 4-week Low
AbbVie's Atogepant And OnabotulinumtoxinA Receive Strong Recommendations In The Newly Updated Canadian Headache Society Migraine Prevention Guideline; A Strong Recommendation Was Issued When An Intervention Was Deemed Suitable For The Majority Of...
Express News | Abbvie's Atogepant and Onabotulinumtoxina Receive Strong Recommendations in the Newly Updated Canadian Headache Society (Chs) Migraine Prevention Guideline